Thomas Goebel joined NeoMed Management in 2005 as a Senior Associate and became a Principal in 2008. He has over 10 years of experience of venture capital investing in healthcare in Europe.

Previously Thomas was a global biotechnology analyst for Pictet & Cie, Switzerland's largest private bank. He was also Manager of Regulatory Affairs with worldwide responsibilities at Firmenich SA, a global leader in fragrances, flavourings and fine chemicals.

Thomas has been a board member of Sequana Medical AG, and a board observer of Novexel SA and currently serves on the board of directors of Diagnoplex SA. 

Thomas holds a Ph.D. in molecular biology form the University of Geneva, Switzerland.